



Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/780,438	02/09/2001	Xiaoyang Qi	

FROST BROWN TODD, LLC
2200 PNC Center
201 East Fifth Street
Cincinnati, OH 45202-4182



CONFIRMATION NO. 7718
FORMALITIES LETTER



OC000000008941817

Date Mailed: 10/11/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. The application must be in sequence compliance before examination on the merits.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: The Office Of Initial Patent Examination.

See the attachment.

Applicant Must Provide as part of the response:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Na

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



PATENT

#13

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application of:

Applicants Xiaoyang Qi

: Paper No:

Serial No. 09/780,438

: Group Art Unit: 1615

Filed: February 9, 2001

: Examiner:

For: FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS
AND POLYPEPTIDES FOR APPLICATION TO TRANSMEMBRANE
DRUG DELIVERY SYSTEM

RESPONSE

THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Dear Sir:

In response to the Office Action, dated October 11, 2002, please consider the following remarks.

Attached hereto, as requested by the Examiner, are additional sequence listings for the above patent application, in compliance with 37 CFR 1.821 - 1.825. In particular, this sequence listing is for those sequences contained in claims 11, 25, 37, and 42, which did not appear in the paper copy or in the CRF copy of the sequence listing. A computer-readable diskette, which contains the sequence listing in ASCII format is also enclosed, along with a written sequence listing which is identical to the electronic sequence listing. These sequence listings correspond to the sequence listings contained in the above-cited application and as such, no new matter is introduced as a result of these corrections.

Respectfully submitted,

XIAOYANG QI, PH.D.

Karlyn A. Schnapp

Karlyn A. Schnapp

Registration No. 45,558

Attorney for Applicant

Telephone (513) 651-6865

FROST BROWN TODD, LLC

2200 PNC Center

201 East Fifth Street

Cincinnati, Ohio 45202-4182

Dated: November 4, 2002

Serial No. 09/780,438



CERTIFICATE OF MAILING

I hereby certify that a copy of this correspondence is being deposited with the United States Postal Service as EXPRESS MAIL in an envelope addressed to The Assistant Commissioner of Patents, Washington, D.C. 20231 this 4th day of November, 2002.


Karen Kruetzkamp

CINlibrary/1230145.1